ArticleBMC global and public health2026
The profile of imported malaria in Sri Lanka from 2013 to 2023.
Article in BMC global and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSri Lanka was certified malaria-free by the World Health Organization in 2016 and has remained so since then. Yet, imported malaria cases and the presence of mosquito vectors in parts of the country threaten the re-establishment of malaria.
methodsData on imported malaria cases diagnosed from 2013 to 2023 in Sri Lanka were extracted from the National Malaria Database containing detailed data on every case of malaria maintained at the Anti Malaria Campaign, Sri Lanka. Descriptive analyses were carried out to characterize imported malaria in the country.
resultsA total of 532 imported malaria cases were reported during the study period, over half of them (68.5%) were those who traveled for employment as low-wage or high-wage workers. Infections with all four human malaria species were imported, with a majority being Plasmodium (P.) falciparum (48.1%), most acquired in Africa, and P. vivax (40.5%), most acquired in India. Imported P. ovale infections took longer to manifest clinically from time of travel (median 95 days) than did other Plasmodia infections (median 14 days). Infections with P. malariae took longer to diagnose from onset of illness (median 15.5 days) than other Plasmodium species (median 4-6 days). Patients accessed healthcare for their malaria illness sooner (geometric mean = 2.42 days) than physicians took to diagnose malaria (geometric mean 3.41 days) (p < 0.001). Seven patients with P. falciparum recrudesced and three with P. vivax relapsed. Forty-six imported malaria cases were severe, all but one due to P. falciparum, and one death occurred among them over the study period. Epidemiological features of imported malaria were species-specific and related to the biology of the Plasmodium species.
conclusionsA large proportion of imported malaria, predominantly P. falciparum and P. vivax, was associated with work-related travel. The parasite species incidence over the years followed trends of incidence reported from Africa and India from where they were predominantly imported. The delay in diagnosing imported malaria which increases the risk of morbidity and mortality, and also risks the re-establishment of malaria in the country were mainly on the part of the physicians and not due to patients delaying seeking treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.